RE-PHIRE
A Phase 2b Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Patients with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)
- Stage
- klaar
- Medicine
- AZD3427
- Population
- Hartfalen
- Phase
- II
- First Patient In
- 11 August 2023
- Last Patient In
- 28 January 2025
- Last Patient Last Visit
- 26 August 2025
National Lead
dr. S. van Wijk
Cardioloog
Study Director